Inicio>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Cefminox sodium

Cefminox sodium

Catalog No.GC61805

El cefminox sÓdico (MT-141) es una cefamicina semisintética que exhibe un amplio espectro de actividad antibacteriana.

Products are for research use only. Not for human use. We do not sell to patients.

Cefminox sodium Chemical Structure

Cas No.: 75498-96-3

Tamaño Precio Disponibilidad Cantidad
10mg
34,00 $
Disponible
25 mg
68,00 $
Disponible
50mg
113,00 $
Disponible
100mg
182,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits a broad spectrum of antibacterial activity[1]. Cefminox sodium (MT-141) also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ, upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium (MT-141) also prevents pulmonary arterial hypertension[2].

[1]. Inouye S, et al. In vitro and in vivo antibacterial activities of MT-141, a new semisynthetic cephamycin, compared with those of five cephalosporins. Antimicrob Agents Chemother. 1984 Nov;26(5):722-9. [2]. Xia J, et al. Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats. Front Pharmacol. 2018 Feb 23;9:134.

Reseñas

Review for Cefminox sodium

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Cefminox sodium

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.